ReviewVaccines2025
Nanovaccines: Innovative Advances from Design Strategies to Clinical Translation.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- The State-of-the Art of Personalized Vaccines for Non-Communicable Diseases: A Narrative Review.Vaccines · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Nanotechnology-Based Cancer Vaccines: Translational Barriers and Emerging Strategies.Vaccines · 2026Review
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- From Innate to Adaptive: Paradigm Shifts and Frontier Challenges in Next-Generation Vaccine Design.Vaccines · 2026Review
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanovaccines have emerged as a transformative platform in immunotherapy, distinguished by their capabilities in targeted antigen delivery, enhanced immunogenicity, and multifunctional integration. By leveraging nanocarriers, these vaccines achieve precise antigen transport, improve immune activation efficiency, and enable synergistic functions such as antigen protection and adjuvant co-delivery. This review comprehensively explores the foundational design principles of nanovaccines, delves into the diversity of nanovaccine design strategies-including the selection of primary carrier materials, functionalization modification, synergistic delivery of immune adjuvants, and self-assembled nano-delivery systems-and highlights their applications in cancer immunotherapy, infectious disease and autoimmune diseases. Furthermore, it critically examines existing technical challenges and translational barriers, providing an integrative reference to guide future research and development in this dynamic field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.